US › Healthcare

Ovid Therapeutics Inc (OVID)

US · Healthcare · Biotechnology

$2.15-4.87%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$733,000

Revenue YoY

-88.3%

Net profit

$-15.0M

EPS

$-0.08

EPS estimate

$-0.10

Net margin

-2,047.6%

EPS came in at -0.08 against a street estimate of -0.10 — a beat of 20.0%.

Key statistics

Market cap

$427.7M

Forward P/E

1.8

P/B

2.40

Book value

$1.14

EPS (TTM)

$-0.22

52-week high

$3.10

52-week low

$1.18

50-day MA

$2.64

200-day MA

$2.32

Beta

0.23

Analyst view

Analysts rate Ovid Therapeutics Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $6.02.

Shareholding

Insiders

6.72%

Institutions

80.42%

Largest institutional holders

Fund	Stake
Jupiter Topco LLC	10.62%
Eventide Asset Management, LLC	6.05%
BlackRock Inc	5.54%
HHG PLC	5.49%
RA Capital Management, LLC	5.38%
Affinity Asset Advisors, LLC	5.19%
State Street Corp	4.05%
Vanguard Capital Management, LLC	3.97%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ovid Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.